Michael Triplett, Ph.D., co-founder, President, and CEO of Armatus Bio, Inc., is passionate about translating world-class science and technology into transformative businesses, Prior to Armatus Bio, Dr. Triplett co-founded two early-stage companies including Myonexus Therapeutics, which was acquired by Sarepta Therapeutics in 2019, and Clarametyx Biosciences, Inc., and served as CEO of N8 Medical. Dr. Triplett previously held roles of progressing responsibility at Battelle Memorial Institute, and began his career at Procter & Gamble, prior to completing graduate work in nanoparticle engineering.

Dr. Triplett currently leads an InnovateOhio Gene and Cell Therapy Working Group for Ohio Lieutenant Governor Jon Husted with the mission of developing gene and cell therapy economic development strategies to grow the industry within the State of Ohio. He earned a B.S. (summa cum laude) and Ph.D. in Chemical Engineering from The Ohio State University as a United States Department of Defense National Defense Science and Engineering Graduate Fellow and University Fellow.